A detailed history of Schroder Investment Management Group transactions in Biogen Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 64,059 shares of BIIB stock, worth $9.55 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
64,059
Previous 35,980 78.04%
Holding current value
$9.55 Million
Previous $8.34 Million 48.88%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$189.07 - $236.8 $5.31 Million - $6.65 Million
28,079 Added 78.04%
64,059 $12.4 Million
Q2 2024

Aug 12, 2024

SELL
$190.52 - $236.72 $8.29 Million - $10.3 Million
-43,509 Reduced 54.74%
35,980 $8.34 Million
Q1 2024

May 14, 2024

SELL
$212.02 - $267.71 $2.79 Million - $3.52 Million
-13,142 Reduced 14.19%
79,489 $17.1 Million
Q4 2023

Feb 13, 2024

BUY
$222.59 - $267.94 $8.45 Million - $10.2 Million
37,948 Added 69.4%
92,631 $24 Million
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $5.39 Million - $6.08 Million
-21,277 Reduced 28.01%
54,683 $14.1 Million
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $520,497 - $601,451
1,891 Added 2.55%
75,960 $21.6 Million
Q1 2023

May 11, 2023

BUY
$256.56 - $292.34 $14.5 Million - $16.5 Million
56,560 Added 323.03%
74,069 $20.6 Million
Q4 2022

Feb 10, 2023

BUY
$252.44 - $306.72 $80,780 - $98,150
320 Added 1.86%
17,509 $4.85 Million
Q3 2022

Nov 10, 2022

SELL
$194.69 - $268.46 $79,628 - $109,800
-409 Reduced 2.32%
17,189 $4.59 Million
Q2 2022

Aug 11, 2022

BUY
$187.54 - $223.02 $545,553 - $648,765
2,909 Added 19.8%
17,598 $3.61 Million
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $956,254 - $1.2 Million
4,935 Added 50.59%
14,689 $3.1 Million
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $223,248 - $286,906
-997 Reduced 9.27%
9,754 $2.34 Million
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $604,183 - $787,921
-2,135 Reduced 16.57%
10,751 $3.04 Million
Q2 2021

Aug 13, 2021

SELL
$259.0 - $414.71 $1.02 Million - $1.64 Million
-3,946 Reduced 23.44%
12,886 $4.46 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $63.8 Million - $74.8 Million
-262,776 Reduced 93.98%
16,832 $4.71 Million
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $38.5 Million - $57.9 Million
-162,832 Reduced 36.8%
279,608 $68.5 Million
Q3 2020

Nov 13, 2020

SELL
$264.77 - $305.71 $42.5 Million - $49.1 Million
-160,597 Reduced 26.63%
442,440 $123 Million
Q2 2020

Aug 13, 2020

BUY
$258.66 - $342.55 $23.1 Million - $30.6 Million
89,405 Added 17.41%
603,037 $161 Million
Q1 2020

May 15, 2020

BUY
$268.85 - $341.04 $7.4 Million - $9.39 Million
27,523 Added 5.66%
513,632 $160 Million
Q4 2019

Feb 11, 2020

SELL
$220.06 - $304.07 $2.45 Million - $3.39 Million
-11,142 Reduced 2.24%
486,109 $144 Million
Q3 2019

Nov 12, 2019

BUY
$217.44 - $243.88 $10.8 Million - $12.1 Million
49,701 Added 11.11%
497,251 $114 Million
Q2 2019

Aug 08, 2019

BUY
$219.29 - $241.72 $11.8 Million - $13 Million
53,605 Added 13.61%
447,550 $105 Million
Q1 2019

May 14, 2019

SELL
$216.71 - $338.96 $4.88 Million - $7.64 Million
-22,535 Reduced 5.41%
393,945 $93.1 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $18.1 Million - $23 Million
-65,125 Reduced 13.52%
416,480 $125 Million
Q3 2018

Nov 13, 2018

SELL
$293.51 - $383.83 $58.8 Million - $76.9 Million
-200,272 Reduced 29.37%
481,605 $170 Million
Q2 2018

Aug 13, 2018

SELL
$257.52 - $306.91 $57.3 Million - $68.3 Million
-222,389 Reduced 24.59%
681,877 $197 Million
Q1 2018

May 11, 2018

BUY
$260.13 - $367.91 $28.2 Million - $39.8 Million
108,297 Added 13.61%
904,266 $248 Million
Q4 2017

Feb 09, 2018

BUY
$307.64 - $344.58 $92.4 Million - $104 Million
300,498 Added 60.65%
795,969 $254 Million
Q3 2017

Nov 09, 2017

BUY
$281.15 - $329.69 $139 Million - $163 Million
495,471
495,471 $154 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.